CTI BioPharma Corp. initiated PRE-VENT, a Phase III study evaluating pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled study, will compare pacritinib plus standard of care (SOC) versus placebo plus standard of care in 358 hospitalized patients with severe COVID-19, including patients with and without cancer. The primary endpoint will assess the proportion of patients who progress to invasive mechanical ventilation and/or extracorpo...